Trinity Biotech’s CGM System Shows Breakthrough Improvements

Trinity Biotech ( (TRIB) ) has shared an update.

On February 6, 2025, Trinity Biotech announced significant improvements in its continuous glucose monitoring (CGM) system, following its latest pre-pivotal trial. The trial demonstrated approximately 35% improvement in Mean Absolute Relative Difference (MARD) and more than 50% in Mean Absolute Difference (MAD) for the first day of use, addressing a key industry pain point. With enhanced accuracy and reliability, these advancements mark a paradigm shift in the CGM market, making the technology more accessible and affordable. Trinity plans further trials and aims for regulatory submissions in Europe in 2025 and the U.S. in 2026, with commercialization efforts focusing on diabetes patients and health-conscious consumers.

More about Trinity Biotech

Trinity Biotech is a commercial-stage biotechnology company specializing in diabetes management solutions and human diagnostics, including wearable biosensors. The company develops, manufactures, and markets diagnostic systems, and has recently entered the wearable biosensor industry with the acquisition of Waveform Technologies Inc. Its products target point-of-care and clinical laboratory markets and are distributed in over 75 countries globally.

YTD Price Performance: -9.26%

Average Trading Volume: 2,237,964

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $9.8M

For an in-depth examination of TRIB stock, go to TipRanks’ Stock Analysis page.